STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Signal transducer and activator of transcription (STAT)3 mediates the signaling downstream of cytokine and growth factor receptors, regulating the expression of target genes. It is constitutively phosphorylated on tyrosine (Y-P) in many tumors, where its transcriptional activity can induce a metabolic switch toward aerobic glycolysis and down-regulate mitochondrial activity, a prominent metabolic feature of most cancer cells, correlating with reduced production of ROS, delayed senescence, and protection from apoptosis. STAT3 can, however, also localize to mitochondria, where its serine-phosphorylated (S-P) form preserves mitochondrial oxidative phosphorylation and controls the opening of the mitochondrial permeability transition pore, also promoting survival and resistance to apoptosis in response to specific signals/oncogenes such as RAS. Thus, downstream of different signals, both nuclear, Y-P STAT3, and mitochondrial, S-P STAT3, can act by promoting cell survival and reducing ROS production. Here, we discuss these properties in the light of potential connections between STAT3-driven alterations of mitochondrial metabolism and the development of drug resistance in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wenz, T., Rossi, S. G., Rotundo, R. L., Spiegelman, B. M., & Moraes, C. T. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911570106 · Cited by 600 · cited 1×
“Moreover, since PGC1α positively regulates mitochondrial biogenesis and respiration, its STAT3-dependent down-regulation may also contribute to decrease mitochondrial activity (49, 50).”
BackgroundRetractedImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452 · cited 1×
“In particular, oxidative damage triggered by enhanced ROS accumulation is a prominent effect of both ionizing radiation and pharmacological agents such as gemcitabine, cisplatin, doxorubicin, and elesclomol (75).”
BackgroundSTATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Wen, Z., Zhong, Z., & Darnell, J. E. (1995) · Cell · doi:10.1016/0092-8674(95)90311-9 · Cited by 1,974
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A., & Semenza, G. L. (2011) · Cell · doi:10.1016/j.cell.2011.03.054 · Cited by 1,463
Triggering and modulation of apoptosis by oxidative stress
Chandra, J., Samali, A., & Orrenius, S. (2000) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00302-6 · Cited by 1,335 · cited 1×
“Excessive oxidative stress can also inhibit caspases activity (111, 112) and drug-induced apoptosis”
BackgroundInduction of Apoptosis by Cancer Chemotherapy
Kaufmann, S. H., & Earnshaw, W. C. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4838 · Cited by 1,266
Cited by
Bharath, L. P., Agrawal, M., McCambridge, G., Nicholas, D. A., Hasturk, H., Liu, J., Jiang, K., Liu, R., Guo, Z., Deeney, J., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.04.015 · Cited by 614
“Phospho-STAT3 serine 727 (p-S727 Stat3), modified for mitochondrial localization (Poli and Camporeale, 2015) co-localized more frequently with the mitochondrial complex 1 subunit NDUFA13/GRIMM19 in cells from O subjects (Figures 6A and 6B), suggesting STAT3 may mediate aging-associated changes in mitochondrial functio…”
Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map
Huynh, J., Chand, A., Gough, D., & Ernst, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 504
Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition
Groner, B., & von Manstein, V. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.033 · Cited by 306
Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment
Poznanski, S. M., Singh, K., Ritchie, T. M., Aguiar, J. A., Fan, I. Y., Portillo, A. L., Rojas, E. A., Vahedi, F., El-Sayes, A., Xing, S., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.023 · Cited by 306
Ganapathy-Kanniappan, S. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1556578 · Cited by 216
Rah, B., Rather, R. A., Bhat, G. R., Baba, A. B., Mushtaq, I., Farooq, M., Yousuf, T., Dar, S. B., Parveen, S., Hassan, R., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.821344 · Cited by 202
Orgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.003 · Cited by 151
“ROS production is counterbalanced by STAT3 (Poli and Camporeale, 2015) and both high myosin II activity and resistant cells harbor high STAT3 signaling (Figure 4E).”
BackgroundInfluentialThe Macrophage Response Is Driven by Mesenchymal Stem Cell-Mediated Metabolic Reprogramming
Luque-Campos, N., Bustamante-Barrientos, F. A., Pradenas, C., García, C., Araya, M. J., Bohaud, C., Contreras-López, R., Elizondo-Vega, R., Djouad, F., Luz-Crawford, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.624746 · Cited by 82
Glutamine activates STAT3 to control cancer cell proliferation independently of glutamine metabolism
Cacace, A., Sboarina, M., Vazeille, T., & Sonveaux, P. (2017) · Oncogene · doi:10.1038/onc.2016.364 · Cited by 76
Metabolic alterations mediated by STAT3 promotes drug persistence in CML
Patel, S. B., Nemkov, T., Stefanoni, D., Benavides, G. A., Bassal, M. A., Crown, B. L., Matkins, V. R., Camacho, V., Kuznetsova, V., Hoang, A. T., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01315-0 · Cited by 56
Baba, Y., Tamura, T., Satoh, Y., Gotou, M., Sawada, H., Ebara, S., Shibuya, K., Soeda, J., & Nakamura, K. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12074 · Cited by 23
“…induced similar ERK/AKT/STAT3 activation, which is considered to mediate prosurvival signaling and be implicated in resistance to these genotoxic agents (McCubrey et al., 2011; Liu et al., 2014; WinogradKatz and Levitzki, 2006; Mabuchi et al., 2002; Taylor et al., 2011; Poli and Camporeale, 2015).”
BackgroundBlocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer
Feng, J., Jiang, W., Liu, Y., Huang, W., Hu, K., Li, K., Chen, J., Ma, C., Sun, Z., & Pang, X. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113960 · Cited by 23
CDK8 fine-tunes IL-6 transcriptional activities by limiting STAT3 resident time at the gene loci
Martinez-Fabregas, J., Wang, L., Pohler, E., Cozzani, A., Kazemian, M., Mitra, S., & Moraga, I. (2020) · doi:10.1101/2020.03.19.998351 · Cited by 2
Metadata
- Authors
- Poli, V., & Camporeale, A.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2015-06-08
- Volume
- 5
- Pages
- 121-121
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W1552924550
- Cited by
- 137
- References
- 26
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.